Literature DB >> 19797117

Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice.

Ericka Diallo-Krou1, Jingcheng Yu, Lesley A Colby, Ken Inoki, John E Wilkinson, Dafydd G Thomas, Thomas J Giordano, Ronald J Koenig.   

Abstract

Approximately 35% of follicular thyroid carcinomas and a small fraction of follicular adenomas are associated with a t(2;3)(q13;p25) chromosomal translocation that fuses paired box gene 8 (PAX8) with the peroxisome proliferator-activated receptor-gamma gene (PPARG), resulting in expression of a PAX8-PPARgamma fusion protein, PPFP. The mechanism by which PPFP contributes to follicular thyroid neoplasia is poorly understood. Therefore, we have created mice with thyroid-specific expression of PPFP. At 1 yr of age, 25% of PPFP mice demonstrate mild thyroid hyperplasia. We bred these mice to mice with thyroid-specific single-allele deletion of the tumor suppressor Pten, denoted ThyPten(+/-). In humans, PTEN deletion is associated with follicular adenomas and carcinomas, and in mice, deletion of one Pten allele causes mild thyroid hyperplasia. We found that PPFP synergizes with ThyPten(+/-) to cause marked thyroid hyperplasia, but carcinomas were not observed. AKT phosphorylation was increased as expected in the ThyPten(+/-) thyroids, and also was increased in the PPFP thyroids and in human PPFP follicular cancers. Staining for the cell cycle marker Ki-67 was increased in the PPFP, ThyPten(+/-), and PPFP;ThyPten(+/-) thyroids compared with wild-type thyroids. Several genes with increased expression in PPFP cancers also were found to be increased in the thyroids of PPFP mice. This transgenic mouse model of thyroidal PPFP expression exhibits properties similar to those of PPFP thyroid cancers. However, the mice develop thyroid hyperplasia, not carcinoma, suggesting that additional events are required to cause follicular thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19797117      PMCID: PMC2775974          DOI: 10.1210/en.2009-0701

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  42 in total

1.  The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition.

Authors:  J Gregory Powell; Xiying Wang; Brandon L Allard; Mustafa Sahin; Xiao-Li Wang; Ian D Hay; Henry J Hiddinga; Seema S Deshpande; Todd G Kroll; Stefan K G Grebe; Norman L Eberhardt; Bryan McIver
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

2.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

3.  Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.

Authors:  Thomas J Giordano; Amy Y M Au; Rork Kuick; Dafydd G Thomas; Daniel R Rhodes; Kenneth G Wilhelm; Michelle Vinco; David E Misek; Donita Sanders; Zhaowen Zhu; Raffaele Ciampi; Samir Hanash; Arul Chinnaiyan; Roderick J Clifton-Bligh; Bruce G Robinson; Yuri E Nikiforov; Ronald J Koenig
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

4.  PAX 8 activates the enhancer of the human thyroperoxidase gene.

Authors:  C Esposito; S Miccadei; A Saiardi; D Civitareale
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

5.  Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis.

Authors:  Hideyo Suzuki; Mark C Willingham; Sheue-Yann Cheng
Journal:  Thyroid       Date:  2002-11       Impact factor: 6.568

6.  Thyrocyte-specific expression of Cre recombinase in transgenic mice.

Authors:  Takashi Kusakabe; Akio Kawaguchi; Rumi Kawaguchi; Lionel Feigenbaum; Shioko Kimura
Journal:  Genesis       Date:  2004-07       Impact factor: 2.487

7.  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas.

Authors:  S M Jhiang; J E Sagartz; Q Tong; J Parker-Thornburg; C C Capen; J Y Cho; S Xing; C Ledent
Journal:  Endocrinology       Date:  1996-01       Impact factor: 4.736

8.  Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment.

Authors:  Joshua P Klopper; William R Hays; Vibha Sharma; Margaret A Baumbusch; Jerome M Hershman; Bryan R Haugen
Journal:  Mol Cancer Ther       Date:  2004-08       Impact factor: 6.261

9.  Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours.

Authors:  A R Marques; C Espadinha; M J Frias; L Roque; A L Catarino; L G Sobrinho; V Leite
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

10.  The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.

Authors:  Laura S Harrington; Greg M Findlay; Alex Gray; Tatiana Tolkacheva; Simon Wigfield; Heike Rebholz; Jill Barnett; Nick R Leslie; Susan Cheng; Peter R Shepherd; Ivan Gout; C Peter Downes; Richard F Lamb
Journal:  J Cell Biol       Date:  2004-07-12       Impact factor: 10.539

View more
  15 in total

1.  Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.

Authors:  Melissa E Dobson; Ericka Diallo-Krou; Vladimir Grachtchouk; Jingcheng Yu; Lesley A Colby; John E Wilkinson; Thomas J Giordano; Ronald J Koenig
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

2.  The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.

Authors:  Dang Vu-Phan; Vladimir Grachtchouk; Jingcheng Yu; Lesley A Colby; Max S Wicha; Ronald J Koenig
Journal:  Endocr Relat Cancer       Date:  2013-09-11       Impact factor: 5.678

Review 3.  Pax-8-PPAR-γ fusion protein in thyroid carcinoma.

Authors:  Priyadarshini Raman; Ronald J Koenig
Journal:  Nat Rev Endocrinol       Date:  2014-07-29       Impact factor: 43.330

4.  Thyroid-Specific PPARγ Deletion Is Benign in the Mouse.

Authors:  Jingcheng Yu; Ronald J Koenig
Journal:  Endocrinology       Date:  2018-03-01       Impact factor: 4.736

Review 5.  Multikinase inhibitors: a new option for the treatment of thyroid cancer.

Authors:  Matti L Gild; Martyn Bullock; Bruce G Robinson; Roderick Clifton-Bligh
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

6.  Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity.

Authors:  Chi-Iou Lin; Justine A Barletta; Matthew A Nehs; Zachary S Morris; David B Donner; Edward E Whang; Jae-wook Jeong; Shioko Kimura; Francis D Moore; Daniel T Ruan
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

Review 7.  Mouse models of thyroid cancer: A 2015 update.

Authors:  Lawrence S Kirschner; Zahida Qamri; Suresh Kari; Amruta Ashtekar
Journal:  Mol Cell Endocrinol       Date:  2015-06-27       Impact factor: 4.102

Review 8.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

Review 9.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.

Authors:  Motoyasu Saji; Matthew D Ringel
Journal:  Mol Cell Endocrinol       Date:  2009-11-06       Impact factor: 4.102

Review 10.  Genetics and epigenetics of sporadic thyroid cancer.

Authors:  Dang Vu-Phan; Ronald J Koenig
Journal:  Mol Cell Endocrinol       Date:  2013-08-08       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.